CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
CATCH
Comprehensive Assessment of Clinical Features and Biomarkers to Identify Patients With Advanced or Metastatic Breast Cancer for Marker Driven Trials in Humans (CATCH)
1 other identifier
observational
5,000
1 country
12
Brief Summary
CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions. Eligible are all metastatic breast cancer patients (independent of gender), irrespective of molecular subtype. At initial diagnosis of distant metastasis or progress at disease progression, biopsy samples from a prognostic-relevant metastasis are retrieved during standard-of-care procedures for central analyses, together with blood samples. In parallel to all standard-diagnostic measures, genomic and transcriptomic profiling is conducted to infer the underlying biology of the disease and identify patients who might profit from biomarker-guided interventions in clinical trials. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform to i) identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) couple the observational, diagnostic registry platform to an increasing number of independent, biomarker-stratified clinical therapy trials (CATCH-GUIDE).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2017
Longer than P75 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 12, 2017
CompletedFirst Submitted
Initial submission to the registry
December 7, 2022
CompletedFirst Posted
Study publicly available on registry
December 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
January 28, 2026
January 1, 2026
13.6 years
December 7, 2022
January 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Setup of the molecular profiling diagnostic platform and feasibility of genomic profiling in metastatic breast cancer.
Total number of advanced stage / metastatic breast cancer patients i) eligible for genomic profiling, ii) successfully genomically-profiled tumors, iii) with conclusive biomarker profiles.
31/12/2030
Total number of patients eligible for clinical trials and targeted therapies based on clinical characteristics and comprehensive tumor features.
Patients enrolled in subsequent interventional clinical therapy trials.
31/12/2030
Secondary Outcomes (1)
Secondary outcome measures Building novel therapeutic hypothesis.
31/12/2030
Interventions
Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
Eligibility Criteria
Advanced-stage / metastatic breast cancer patients (at the time point of progress)
You may qualify if:
- Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
- Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
- Patients, who agreed to and were able to sign the informed consent form.
You may not qualify if:
- Early breast cancer
- Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
- Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- German Cancer Research Centerlead
- University Hospital Heidelbergcollaborator
Study Sites (12)
University Hospital Augsburg
Augsburg, Germany
Charité
Berlin, Germany
University Hospital Köln
Cologne, Germany
Medical Faculty and University Hospital Carl Gustav Carus
Dresden, Germany
University Hospital Erlangen
Erlangen, Germany
University Hospital Essen
Essen, Germany
National Center for Tumor Diseases
Heidelberg, Germany
Caritas Hospital St. Josef
Regensburg, Germany
Robert-Bosch-Krankenhaus Stuttgart
Stuttgart, Germany
University Hospital Tübingen
Tübingen, Germany
University Hospital Ulm
Ulm, Germany
University Hospital Würzburg
Würzburg, Germany
Biospecimen
Fresh-frozen biopsy tissue and EDTA-blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andreas Schneeweiss, MD
National Center for Tumor Diseases, Heidelberg
- PRINCIPAL INVESTIGATOR
Peter Lichter, PhD
German Cancer Research Center
- PRINCIPAL INVESTIGATOR
Verena Thewes, PhD
National Center for Tumor Diseases, Heidelberg
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 7, 2022
First Posted
December 15, 2022
Study Start
June 12, 2017
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
January 28, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share